Premium
Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia
Author(s) -
Kline Ronald M.,
Buck Laura Marcu
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21860
Subject(s) - medicine , bevacizumab , natural history , vascular endothelial growth factor , lymphatic system , platelet , disease , pathology , vascular disease , chemotherapy , vegf receptors
Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) is a rare disorder characterized by a proliferation of cutaneous and gastrointestinal (GI) lesions that have characteristics of both lymphatic and vascular lesions. Thrombocytopenia is associated with this syndrome and is thought to represent platelet destruction within the lesions. The natural history is one of multiple, life‐threatening episodes of GI bleeding. We report the successful use of bevacizumab in this disease, an antibody to the vascular endothelial growth factor. Pediatr Blood Cancer 2009;52:534–536. © 2008 Wiley‐Liss, Inc.